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Abstract 
Urogenital tract cancers including ovarian, cervical, kidney and bladder carcinomas are among 
the most common and lethal cancers worldwide. Numerous factors could be involved in 
urogenital cancer development, including genetic predisposition, lifestyle, and infectious agents. 
Approximately 15% of cancers worldwide are caused by microorganisms [1], but growing 
evidence indicates this number might be much higher. This article reviews literature available to 
date on the role of microorganisms in urogenital tract cancers. A greater understanding of the 
function of such microorganisms in promoting carcinogenesis is required to aid identification of 
novel strategies for cancer treatment. 
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Ovarian cancer 
Ovarian carcinoma is a common human tumor of the genital tract and one of the most lethal 
cancers worldwide [2]. In 2008, ovarian carcinoma was the 2nd most lethal gynecological cancer 
[3]. The molecular events occurring during early stages of ovarian carcinogenesis are not well 
understood due to the absence of symptoms in patients and the site of origins of neoplastic 
lesions. Most patients are diagnosed with ovarian cancer when the tumor is at an advanced stage 
and has metastasized to the peritoneum. The prognosis of ovarian cancer is therefore poor. 
Moreover, ovarian cancers rapidly develop resistance to cytotoxic drugs [4]. Piek et al. [5] list 
three possible routes of ovarian carcinogenesis: ovarian surface epithelial tissue, embryologic 
Mullerian ducts, and the inner surface epithelium of the Fallopian tube. 
Most aggressive ovarian carcinomas arise from ovarian surface epithelium (OSE) cells and 
account for about 60% of all ovarian carcinomas. Non-epithelial ovarian tumors arising from 
oocytes and sex cord stromal cells usually remain benign. Thus, ovarian epithelial tumors receive 
greater attention, and multiple studies are currently underway to determine the origins of 
neoplastic lesions in the OSE and understand the early molecular events of the disease. Two 
broadly accepted theories of OSE carcinogenesis are incessant ovulation and gonadotropin. The 
incessant ovulation theory suggests the epithelium may be more apt to mutate with each 
ovulation and failure to break the cycle, as in pregnancy, increases the chance of mutation. The 
gonadotropin theory suggests elevated gonadotropin levels trigger proliferation of the ovarian 
epithelium, with subsequent malignant transformation. Epidemiological data available to date do 
not provide sufficient evidence for either theory [6,7]. 
In a third theory, Ness and Cottreau [8] suggested that inflammatory-like processes, occurring 
during ovulation and mediated by gonadotropins, underlie higher cancer risks associated with 
ovulation and gonadotropin stimulation. This inflammation theory is supported by several 
epidemiological studies focused on mechanisms that did not affect hormone levels and ovulation, 
including effects of asbestos and talc exposure, prophylactic hysterectomy and tubal ligation, 
pelvic inflammatory disease and endometriosis [9-17]. It was previously established that chronic 
inflammation, a response of the organism to pathogens or irritants, could lead to neoplastic 
transformation of inflamed tissues due to host defense mechanisms and their products, which 
were thought to have antimicrobial properties [18]. During inflammation, mutagenic substances 
such as reactive oxygen and nitrogen species are released by neutrophils and macrophages and 
play a crucial role in promoting carcinogenesis. These species can directly damage DNA by 
oxidation and nitration, and modify cancer-related proteins [19]. In combination with elevated 
levels of cell proliferation for repair of damaged tissue, these changes create favorable conditions 
for increased transformation. 
Apoptosis is another critical cellular mechanism that eliminates damaged or unwanted cells by 
directing them to undergo programmed cell death. It is also a vital process that contributes 
significantly to the protection from tumor formation. Thus inhibition of apoptosis increases the 
risk of malignancy, and it was found that cells infected with Chlamydia 
trachomatis (C.trachomatis) and human papillomavirus (HPV) are resistant to apoptosis [20,21]. 
Various microorganisms involved in sexually transmitted diseases, including C.trachomatis and 
Mycoplasma genitalium (M.genitalium), have been associated with a higher risk for ovarian 
cancer [22,23]. These pathogens cause chronic and asymptomatic infection, increasing the risk of 
neoplastic transformation of the OSE. These pathogens are also associated with pelvic 
inflammatory disease (PID) and tubal infertility factor (TIF), suggesting they can traverse from 
the lower to upper genital tract infecting and causing persistent inflammation in the Fallopian 
tubes and ovaries. These associations indicate that more attention should be paid to the role of 
these pathogens in ovarian cancer. 
C.trachomatis is the most prevalent infection of the genital tract in women worldwide, and the 
disease is usually asymptomatic [24]. It is possible to suggest that cells infected by chlamydia 
have a much higher risk of neoplastic transformation because the pathogen is able to cause 
persistent inflammation and hence tissue damage, and has an antiapoptotic activity on infected 
cells [21]. Chlamydia is an obligatory intracellular pathogen and can replicate only inside a 
cytoplasmic vacuole (phagosome) of the host cell. It is able to cause chronic asymptomatic 
infection due to the fact that it can evade the host immune response by preventing the fusion of 
the phagosome with a lysosome by an unknown mechanism [25], by inhibiting expression of the 
host cell’s major histocompatibility complex antigen [26-29], and by blocking pathways to 
apoptosis. In the study by Greene et al. [16], serovars of C. trachomatis and C.psittaci were 
analyzed and inhibition of apoptosis of infected cells in cultures was observed. Moreover, the 
authors observed that DNA synthesis was unaffected in infected cells and infected cells could 
undergo mitosis at any stage of infection which also increases the risk of malignant 
transformation of infected cells. The mechanisms and key players involved in blocking apoptosis 
in infected cells require further investigation. Some studies [30,31] suggest that chlamydia heat 
shock protein (a major cause of persistent inflammation) might have antiapoptotic activity. 
Serum antibodies to this protein were elevated in women with TFI [32]. Cooper et al. [33] 
observed that chlamydia also has a cytotoxic effect on cells promoting loss of microvilli and cell 
junctions, likely by producing a toxin (homologous to large clostridial cytotoxin) [34]. Loss of 
cell adhesion resulting from the loss of cell junctions induces selection of preneoplastic cells. It 
remains to be determined whether other bacterial toxins or proteins that can affect the host cell’s 
DNA directly. 
M.genitalium is well associated with PID and TFI, and could also cause chronic asymptomatic 
infection in the upper genital tract. M.genitalium might increase the risk of neoplastic 
transformation of tubal and ovarian tissue. However, Idahl et al. [23] did not find an association 
between M.genitalium antibodies and ovarian tumors. Nonetheless, prolonged infection could 
cause morphological changes in mammalian host cells. A study by Baczynska et al. [35], 
demonstrated that Mycoplasma hominis (M.hominis) andM.genitalium caused swelling of the 
tubal epithelial cilia through production of a toxin or metabolism products – hydrogen peroxide 
and superoxide radicals. This is consistent with finding of recent studies suggesting some serous 
ovarian carcinomas (the most aggressive ovarian carcinoma) can originate from the Fallopian 
tube epithelium [5,36]. Another study by Namiki et al. [37] demonstrated that prolonged 
infection of benign human prostate cells in culture with M.genitalium and Mycoplasma 
hyorhinis caused malignant transformation through an unknown mechanism. 
Neisseria gonorrhea (N.gonorroea) is a facultative intracellular pathogen that attaches to the 
apical surface of the genital tract epithelium. Neisseria gonorrhea has not been associated with 
ovarian cancer so far. However, the attachment of the pathogen to the epithelium of the genital 
tract provokes various cell signaling events and alters expression of many cellular proteins, 
which might predispose them to malignant transformation. N.gonorrhoea alters cell cycle 
progression by reducing expression of cyclin B and arresting cells in the G1 phase of the cell 
cycle [38]. Löfmark et al. [39] investigated Me-180 (cervical carcinoma cell line) and HEC-1-B 
(endometrial adenocarcinoma cell line) cells infected with N.gonorrhoea and examined their 
levels of amphiregulin expression. Amphiregulin is an epidermal growth factor receptor ligand, 
expressed in the G1 stage that promotes cellular growth and cell cycle progression. The role of 
amphiregulin in various cancers has been extensively investigated. Amphiregulin appears to 
contribute to tumorigenesis by promoting independent production of growth signals, limitless 
proliferation, tissue invasion and metastasis, angiogenesis, and resistance to apoptosis (reviewed 
in [40]). Amphiregulin was expressed at higher rates following infection in Me-180 and HEC-1-
B cell lines. However, the effect of amphiregulin on OSE cells and the ability 
of N.gonorrhoea to cause their malignant transformation require elucidation. 
A recent study by Shanmughapriya, et al. [41], showed HPV and cytomegalovirus (CMV) DNA 
were present in fresh ovarian carcinoma tissue samples in 40% and 50% of samples, 
respectively. The samples were collected from 39 women in total. The authors assumed that the 
HPV infection could arise from HPV-coated sperm that contact upper genital tract tissues. 
Ovarian CMV infections are quite rare and the authors therefore suggest that activation of the 
virus occurs during immunocompromised states that may occur following chemotherapy, 
radiotherapy, and metastatic disease. It was suggested that human cytomegalovirus is able to 
induce oncomodulation in infected cells, in other words the virus creates a more malignant 
phenotype of tumor cells by the action of its regulatory proteins and non-coding RNA which will 
affect their proliferation, invasion of other tissues, survival and other cellular properties [42]. 
However further investigation is necessary to determine whether ovaries are the primary site of 
CMV infection. 
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Cervical cancer 
Cervical cancer arises in the cervix uteri and is the most prevalent gynaecological malignancy 
worldwide [2]. HPV infection with high-risk HPV (16 and 18) is one of the most common causes 
of cervical cancer [43], other pathogens like C.trachomatis[44] and Epstein-Barr virus [45-47] 
were also found to be implicated in cervical carcinoma acting either independently or as co-
factors in predisposing cervical epithelial cells to malignancy. Other factors that increase the risk 
of developing cervical carcinoma are genetic predisposition, smoking, weakened immunity, life 
style. 
HPV is a small DNA virus that infects various epithelial tissues, and two types of the virus, HPV 
16 and 18, are responsible for 70% of cervical carcinomas [43]. The virus inserts itself into 
human DNA, producing proteins that cause neoplastic transformation of the cervical epithelial 
cells. The key players involved in this process are early proteins 6 and 7 (E6 and E7), which are 
produced by HPV 16 and HPV 18 respectively. The viral DNA does not disrupt any human 
genes; instead, protein products of the viral genes - E6 and E7 proteins bind to the human tumor-
suppressor proteins p53 and pRb, respectively, and inactivate them by promoting protein 
degradation (reviewed in [31]). Inactivation of these tumor-suppressors eventually leads to 
accumulation of mutations and onset of cancer. However, transient HPV infection is not 
sufficient to cause cervical neoplasia; it was previously observed that the infection could be 
cleared in most women [48,49]. The infection has to be persistent to cause transformation. 
As some studies have shown, C.trachomatis increases the risk of HPV infection becoming 
persistent by increasing HPV’s access to the basal epithelium due to microabrasions of the 
cervical epithelium or changing its characteristics, or by preventing efficient clearance of the 
viral infection [50,51]. Also a study by Lehtinen et al. [44] demonstrated that C.trachomatis 
infection was an independent risk factor for cervical neoplasia. This could be because the 
pathogen blocks pathways to apoptosis in infected cells while promoting their entry to the S 
phase, causing chronic inflammation. Other sexually transmitted diseases could play a similar 
role to C.trachomatis, leading to persistence of HPV infection. The mechanisms involved in this 
process still need to be determined. 
The correlation between Epstein-Barr virus (EBV) infection and uterine cervical cancer has been 
reported in several studies [45-47]. The role of EBV in cervical cancer was tested by examining 
the presence and expression of EBV genes in cervical carcinoma and normal cervical tissue. The 
EBV genome was present in 55% (17 of 31) of carcinoma samples and in 26% (9/35) of normal 
samples [45]. A later study used mRNA in situ hybridization to detect mRNA of EBV nuclear 
antigen 2 in tissue samples from patients with invasive uterine cervical cancer and cervical 
intraepithelial neoplasia [46]. The authors found EBV nuclear antigen-2 (EBNA2) mRNA in 
these samples; furthermore, they detected expression of EBNA leader protein 2c by using 
mRNA in situ hybridization and indirect immunofluorescent staining [47]. Another study 
demonstrated the significance of cervical co-infection with HPV 16 and EBV in uterine cervical 
cancer patients: all patients carried IgG-anti-VCA and IgG-anti-EBNA serum and more than 
30% (of 48 patients) were also infected with HPV 16 [52]. 
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Kidney cancer 
Kidney cancer includes renal cell carcinoma (RCC) and renal pelvis carcinoma, and it also 
includes Wilms tumor, a type of kidney cancer that usually develops in children under the age of 
5. According to the International Agency for Research on Cancer in 2008, the global incidence 
of kidney cancer was 273,518 cases (2.3% of all cancer cases) and mortality was at 116,368 
cases (1.5% of all cancer mortality cases) making RCC 11th most frequent cancer worldwide. 
Several studies have revealed an association between kidney cancer and viruses. The World 
Health Organization estimated that 130–170 million people are chronically infected with 
hepatitis C virus (HCV), a major cause of cirrhosis, liver failure, and hepatocellular carcinoma. 
A study by Gordon et al. [53] compared incidences of RCC between anti-HCV positive adults 
and an anti-HCV negative control group, and found that chronic infection with HCV was 
associated with an increased risk of RCC. In addition, the seroprevalence of HCV in patients 
with RCC who participated in the cohort study by Gordon et al. was higher than the overall 
seroprevalence of HCV in the United States (4.3% and 1.6% respectively). 
Interestingly, the results of study by Salehipoor et al. [54] suggested an association between 
high-risk types of HPV and RCC. In this study, nested PCR was used to detect HPV in 49 
patients with clinical and histopathological diagnoses of RCC. Subsequently, 14.29% of RCC 
tissues tested positive for HPV, but no expression of EBV was detected in the control group. All 
of the detected HPV types were high-risk ones (type 16 in 3 and 18 in 4 patients). 
In concordance with the above findings, results from several studies suggested the involvement 
of EBV in RCC pathogenesis. In a study by Shimakage et al. [55], EBV mRNA was detected in 
RCC and nephroblastoma by in situ hybridization. The expression of EBV was stronger in clear-
cell type and papillary RCC than in chromophobe cell type RCC. 
Urinary tract infection history was also shown to play a role in kidney cancer development, as 
Parker et al. [56] reported a positive association of urinary tract infection history with the risk of 
renal cell carcinoma development. Urinary tract infection history was also shown to play a role 
in kidney cancer development, as Parker et al. [56] reported a positive association between the 
risk of RCC development and a history of urinary tract infections in patients. 
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Bladder cancer 
Urinary bladder cancer can be divided into distinct types, including transitional cell carcinoma 
(the most common), squamous cell carcinoma and adenocarcinoma. Bladder cancer is the 7th 
most common cancer among males and 17th most common malignancy in females. In 2008, 
bladder cancer was the 9th most common cancer globally [57]. 
Urinary forms of schistosomiasis that is caused by Schistosoma haematobium (S.haematobium) 
is an infection commonly associated with an increased risk for urinary bladder cancer. An 
association between schistosomiasis and urinary bladder cancer is particularly evident in Egypt, 
where schistosomiasis is endemic. The overall prevalence of S.haematobium infection in Egypt 
is 37-48% [58]. Urinary bladder cancer is the most common type of cancer in males, and 2nd 
most common in females, and accounts for nearly 3% of the total cancer incidence in Egypt 
(compared to the 5-7th most common cancer in males and 7-14th most common cancer in 
females in schistosoma-free countries) [58]. 
Studies conducted by the International Agency for Research on Cancer (IARC) [59] revealed 
that infections with S.haematobium predisposed patients to bladder cancer, in particular, 
squamous cell carcinoma. Individuals heavily infected with S.haematobium were more likely to 
develop bladder cancer, and at a younger age. Bedwani et al. [60] studied the relationship 
between the clinical history of schistosomiasis and risk for bladder cancer by analyzing data 
from case–control studies involving 190 bladder cancer patients and 187 control subjects with 
non-urinary tract conditions. The study showed that schistosomiasis was associated with an 
increased risk of bladder cancer and accounted for 16% of bladder cancer cases in that Egyptian 
population. 
Urinary bladder cancer was also shown to be associated with viruses. For example, a meta-
analysis [61] revealed that infections with high-risk HPV (HR-HPV) types, especially HPV16, 
might play a significant role in bladder carcinogenesis. Various studies led to the detection of 
HPV DNA in benign and malignant neoplasms of the bladder [62-65]. Barghi et al. [66] found 
HPV DNA in 36% of transitional-cell bladder cancer specimens. Moonen et al. [67] detected 
HPV DNA in 15% of urinary bladder cancer patients, and HR-HPV DNA in 8% of patients 
(from a total of 107 patients). The number of specimens positive for HR-HPV DNA increased 
with the clinical progression of the disease, with HR-HPV detected in 0% of Ta, 12.5% of T1, 
and 18.2% of T2-T4 stage bladder cancers. HPV16 and HPV18 DNA were detected in nearly 
50% of urinary bladder dysplasia and carcinoma specimens when examined using in 
situ hybridization [68]. In another study, HPV16 genetic material was found in 40% of 
transitional bladder cancer specimens [69]. Despite the results of these studies, the IARC 
concluded that there is “inadequate evidence” to support a role of HPV in bladder 
carcinogenesis. The human polyomaviruses BKV and JCV establish persistent infections in 
humans and possess oncogenic and transforming potential in experimental animal models and 
cell cultures [54]. The presence of BKV and JCV were detected in urothelial carcinomas of the 
renal pelvis RCCs [69]. However, no definitive association between BKV and human cancers 
has been established to date [70,71]. Shen et al. [72], detected JCV DNA using nested PCR in 
90.1% (30 out of 33) urothelial carcinoma tissue samples and in 100% (5 out of 5) renal cell 
carcinoma samples. BKV DNA was detected in only one (3%) urothelial carcinoma tissue 
sample. Geetha et al. [73], detected elevated levels of BKV large T antigen expression in a 
bladder carcinoma developed in a simultaneous kidney and pancreas transplant recipient. Such 
levels were not observed in non-neoplastic urothelium. Based on these findings, the authors 
suggested that BKV virus might function as an etiologic agent in the development of urinary 
bladder carcinoma. 
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Conclusion 
A growing body of evidence indicates that some viruses, bacteria and even helminths might 
increase cancer risk by promoting general inflammation and subsequently affecting key cellular 
processes. However, the exact mechanisms by which the products of how pathogens promote or 
predispose cells to neoplastic transformation are unknown. One exception is HPV, which has 
been shown to induce carcinogenesis in cervical epithelial cells by inactivating tumor suppressor 
proteins. However, in cases of ovarian, kidney and bladder cancer we can only infer a role for 
infectious agents based on their associations with these cancers. More in-depth and mechanistic 
studies are required to understand the molecular mechanisms, by which infectious agents could 
promote carcinogenesis. Such studies could lead to identification of novel methods of urogenital 
cancer treatment. 
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